
Moderna Covid-19 vaccine progress lifts stock markets
A week after Pfizer announced that its Covid-19 vaccine was more than 90 per cent effective, Moderna also announced preliminary data from its late-stage trials that showed that its candidate has an efficacy of 94.5 per cent. As a result, the vaccine developer saw its shares jump by 9.58 per cent on Tuesday. On Monday, the company’s shares rose as much as 17.8 per cent. Moderna received significant funding from the US government to develop its vaccine and was part of Trump administration’s vaccine initiative called ‘Operation Warp Speed’.
The United States’ top infectious disease scientist Anthony Fauci hailed the announcement and called it “stunningly impressive.” Fauci told AFP, “The idea that we have a 94.5 percent effective vaccine is stunningly impressive. It is really a spectacular result that I don’t think anybody had anticipated would be this good.”
Not only Moderna’s shares but US stocks also jumped nearing a record 30,000 on the Dow as the news comes amid rising coronavirus cases in the country. The Dow Jones Industrial Average gained more than 400 points to close at an all-time high of 28,880. The broader S&P 500 also set a record high above 3,619 points, while in Toronto the S&P/TSX Composite Index gained more than 200 points or 1.3 per cent to close at 16,889. Industries that have been the hardest hit by the pandemic, including the energy sector and anything to do with travel and tourism, rebounded most. The price of a barrel of oil gained about three per cent to $41.24 US a barrel.
Read more | Covid-19: Pfizer, Moderna plan to supply millions of vaccine doses
The news caused the stocks to soar as Moderna appears well on its way toward grabbing an Emergency Use Authorization from the Food and Drug Administration for mRNA-1273, perhaps before the end of the year. So, if this timeline holds, Moderna’s Covid-19 vaccine may be ready for widespread public distribution sometime in January 2021. The company also said that it has approximately 20 million doses ready to ship within the US by the end of 2020. Another 500 million to 1 billion doses of the vaccines are expected to be manufactured for global distribution over the course of 2021.
Experts believe that the announcement sent stock markets soaring as a vaccine development is being seen as “a beginning to the end” of the pandemic.
Yesterday, Asian stocks had also hit a record high as vaccine optimism and strong economic data from China and Japan outshone worries about rising coronavirus cases.
Watch: Trump claims credit after Moderna claims its vaccine is 94.5% effective

India within striking distance of attaining positive growth, says RBI

Saudi Aramco excludes emissions data in disclosures to investors

$200 bn extra savings, lockdown boosts household savings to 20-yr high: Report

Rupee gains 6 paise to close near 5-month high of 72.99 vs USD

Budget 2021: CII seeks customs duty exemption for defence imports in pvt sector

Sensex breaches 50k-mark, ends lower on profit-booking

India still hopes oil majors will join race for biggest sale

India has been through worst of Covid-19, barring another wave, says RBI

From 26,000 to 50,000: Tracing Sensex's journey to record high in last 10 months

Hopes fade for turnaround in Asia’s worst-performing currency of 2020

Bitcoin falters for a second day, slides below technical level

Future Retail, Enterprises hit upper circuit after Sebi clears deal with RIL

Gadkari says govt to bring law to ensure MSME dues are paid within 45 days

Rupee gains 7 paise to trade near 5-month high of 72.98 vs USD
